Rectal cancer: Current status of multimodal therapy when and how?;Rektumkarzinom: Aktueller Stand der multimodalen Therapie wann und wie?

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 4, 2011, Pages 334-342

  Gaedcke, J ^a   Liersch, T ^a   Hess, C ^a   Becker, H ^a   Rodel C ^b   Ghadimi, B M ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

algorithms; multimodal therapy; preoperative radiochemotherapy; rectal cancer

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLUOROURACIL; TUMOR MARKER;

ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ALGORITHM; ARTICLE; BLOOD; HUMAN; LIVER TUMOR; METASTASIS; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM TUMOR; RISK ASSESSMENT; SURVIVAL RATE; TUMOR RECURRENCE;

ALGORITHMS; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMORADIOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; FLUOROURACIL; HUMANS; INDIVIDUALIZED MEDICINE; LIVER NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; RISK ADJUSTMENT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 80052155853     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1271581     Document Type: Article

References (107)

1. Heald R J., Husband E M., Ryall R D. The mesorectum in rectal cancer surgery the clue to pelvic recurrence? Br J Surg 1982 69 613-616 (Pubitemid 12038080)
2. MacFarlane J K., Ryall R D., Heald R J. Mesorectal excision for rectal cancer. Lancet 1993 341 457-460 (Pubitemid 23054519)
3. Havenga K, Enker W E., Norstein J et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411patients. Eur J Surg Oncol 1999 25 368-374 (Pubitemid 29364222)
4. Kapiteijn E, Marijnen C A., Nagtegaal I D. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. NEngl J Med 2001 345 638-646
5. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. NEJM 2004 17 1731-1740
6. Roh M S., Colangelo L H., OConnell M J. et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 2009 27 5124-5130
7. ndEuropean Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009 92 148-163
8. Rödel C, Arnold D, Liersch T. Rectal Cancer. In: Blanke C D. et al. Hrsg Gastrointestinal Oncology A Practical Guide. Berlin Heidelberg Springer 2011 379-422
9. Schmiegel W, Reinacher-Schick A et al. [Update S3-guideline colorectal cancer 2008]. Z Gastroenterol 2008 46 799-840
10. Sauer R, Liersch T, Merkel S et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phaseIII trial after a median follow up of 11years. ASCO Annual Meeting, abstract 80285 2011
11. Gérard J P., Azria D, Gourgou-Bourgade S et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phaseIII trial ACCORD 12/0405-Prodige2. J Clin Oncol 2010 28 1638-1644
12. Gerard J P., Conroy T, Bonnetain F et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T34 rectal cancers: results of FFCD 9203. J Clin Oncol 2006 24 4620-4625 (Pubitemid 46630960)
13. Bosset J F., Collette L, Calais G, et al., for the EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006 355 1114-1123 (Pubitemid 44394918)
14. Augestad K M., Lindsetmo R O., Stulberg J et al. International preoperative rectal cancer management: Staging, neoadjuvant treatment, and impact of multidisciplinary teams. World J Surg 2010 34 2689-2700
15. Liersch T, Rothe H, Ghadimi B M. et al. Therapie beim lokal fortgeschrittenen Rektumkarzinom Ansätze zur Individualisierung. Chirurg 2009 80 281-293
16. Sebag-Montefiore D, Stephens R J., Steele R et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009 373 811-820
17. Peeters K C., Marijnen C A., Nagtegaal I D. et al. The TME trial after a median follow-up of 6years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007 246 693-701 (Pubitemid 350035641)
18. Bujko K, Nowacki M P., Nasierowska-Guttmejer A et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006 93 1215-1223 (Pubitemid 44547018)
19. Bujko K, Nowacki M P., Nasierowska-Guttmejer A et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004 72 15-24 (Pubitemid 38952855)
20. Soreide O, Norstein J, Fielding L P. et al. International standardization and documentation of the treatment of rectal cancer. In: Soreide O Norstein J Eds. Rectal cancer surgery. Optimisation standardisation documentation. Berlin, Heidelberg, New York Springer 1997 405-445
21. Sobin L H., Gospodarowicz M K., Wittekind D. UICC: TNM classification of malignant tumors. 7 th edition Oxford Wiley-Blackwell 2009
22. Edge S B., Byrd D R., Compton C C. et al. AJCC cancer staging manual. 7th ed. New York Springer 2010
23. Vorwerk H, Liersch T, Rothe H et al. Gold markers for tumor localization and target volume delineation in radiotherapy for rectal cancer. Strahlenther Onkol 2009 185 127-133
24. Beets-Tan R G., Beets G L. Preoperative staging of rectal tumors: what is the most optimal staging method? Onkologie 2008 31 222-223 (Pubitemid 351744819)
25. MERCURY Study Group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 2007 243 132-139
26. Kim N K., Kim M J., Yun S H. et al. Comparative study of transrectal ultrasonography, pelvic computerized tomography, and magnetic resonance imaging in preoperative staging of rectal cancer. Dis Colon Rectum 1999 42 770-775 (Pubitemid 29279429)
27. Harewood G C., Wiersema M J., Nelson H et al. A prospective, blinded assessment of the impact of preoperative staging on the management of rectal cancer. Gastroenterology 2002 123 24-32 (Pubitemid 34747522)
28. Kulinna C, Scheidler J, Strauss T et al. Local staging of rectal cancer: assessment with double-contrast multislice computed tomography and transrectal ultrasound. J Comput Assist Tomogr 2004 28 123-130 (Pubitemid 38057867)
29. Taylor A, Slater A, Mapstone N et al. Staging rectal cancer: MRI compared to MDCT. Abdom Imaging 2007 32 323-327 (Pubitemid 47077097)
30. Vliegen R, Dresen R, Beets G et al. The accuracy of Multi-detector row CT for the assessment of tumor invasion of the mesorectal fascia in primary rectal cancer. Abdom Imaging 2008 33 604-610
31. M.E.R.C.U.R.Y. Project (Magnetic Resonance Imaging and Rectal Cancer European Equivalence Study). 2002 Study Protocol. (Study Coordinator I.Daniels, FRCS, Pelican Centre, North Hampshire Hospital, Basingstoke, Hampshire, UK) http://www.pelicancancer.org/researchprojects
32. Barbaro B, Fiorucci C, Tebala C et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009 250 730-739
33. Lahaye M J., Engelen S M., Kessels A G. et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 2008 246 804-811
34. 18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J 2010 86 174-182
35. Hillner B E., Siegel B A., Shields A F. et al. The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 2009 115 410-418
36. Weber W A., Figlin R. Monitoring cancer treatment with PET/CT: does it make a difference? J Nucl Med 2007 48 36S-44S (Pubitemid 47604941)
37. Wahl R L., Jacene H, Kasamon Y et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009 50 122S-150S
38. Bosset J F., Calais G, Mineur L et al. Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results EORTC 22921. J Clin Oncol 2005 23 5620-5627
39. Bosset J F., Collette L, Calais G et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006 355 1114-1123 (Pubitemid 44394918)
40. Frykholm G J., Pahlman L, Glimelius B. Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 2001 50 427-434
41. Arbman G, Nilsson E, Hallbook O et al. Local recurrence following total mesorectal excision for rectal cancer. Br J Surg 1996 83 375-379 (Pubitemid 26083175)
42. Dahlberg M, Glimelius B, Pahlman L. Changing strategy for rectal cancer is associated with improved outcome. Br J Surg 1999 86 379-384 (Pubitemid 29145927)
43. Wibe A, Moller B, Norstein J et al. A national strategic change in treatment policy for rectal cancer implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002 45 857-866 (Pubitemid 34761463)
44. Porter G A., Soskolne C L., Yakimets W W. et al. Surgeon-related factors and outcome in rectal cancer. Ann Surg 1998 227 157-167 (Pubitemid 28087906)
45. Hermanek P, Hohenberger W, Klimpfinger M et al. The pathological assessment of mesorectal excision: implications for further treatment and quality management. Int J Colorectal Dis 2003 18 335-341 (Pubitemid 36790231)
46. Stockholm Rectal Cancer Study Group. Preoperative short-term radiation therapy in operable rectal carcinoma. A prospective randomized trial. Cancer 1990 66 49-55
47. Stockholm Colorectal Cancer Study Group. Randomized study on preoperative radiotherapy in rectal carcinoma. Ann Surg Oncol 1996 3 423-430
48. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997 336 980-987
49. Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicenter trial. Ann Surg 1990 211 187-195 (Pubitemid 20063206)
50. Peeters K C., Marijnen C A., Nagtegaal I D. et al. The TME trial after a median follow-up of 6years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007 246 693-701 (Pubitemid 350035641)
51. Marijnen C A., Nagtegaal I D., Klein Kranenbarg E et al. No downstaging after short-term preoperative radiotherapy in rectal cancer patients. JClin Oncol 2001 19 1976-1984 (Pubitemid 32702542)
52. Rodel C, Martus P, Papadoupolos T et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 2005 23 8688-8696 (Pubitemid 46211512)
53. Maas M, Nelemans P J., Valentini V et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 2010 11 835-844
54. Capirci C, Valentini V, Cionini L et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566ypCR patients. Int J Radiat Oncol Biol Phys 2008 72 99-107
55. Rodel C, Grabenbauer G G., Papadopoulos T et al. PhaseI/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. J Clin Oncol 2003 21 3098-3104 (Pubitemid 46613485)
56. Rodel C, Liersch T, Hermann R M. et al. Multicenter phaseII trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 2007 25 110-117 (Pubitemid 350003058)
57. Hofheinz R D., von Gerstenberg-Helldorf B, Wenz F et al. PhaseI trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005 23 1350-1357
58. Rodel C, Arnold D, Hipp M et al. PhaseIII trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008 70 1081-1086 (Pubitemid 351296110)
59. Horisberger K, Treschl A, Mai S et al. Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a PhaseII MARGIT trial. Int J Radiat Oncol Biol Phys 2009 74 1487-1493
60. Bertolini F, Chiara S, Bengala C et al. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phaseII study in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2009 73 466-472
61. Debucquoy A, Haustermans K, Daemen A et al. Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. J Clin Oncol 2009 27 2751-2757
62. Weiss C, Arnold D, Dellas K et al. Preoperative radiotherapy of advanced rectal cancer with capecitabine and oxaliplatin with or without cetuximab: A pooled analysis of three prospective phaseIII trials. Int J Radiat Oncol Biol Phys 2010 78 472-478
63. Roedel C, Becker H, Fietkau R et al. Preoperative chemoradiotherapy and postoperative chemotherapy with 5-fluorouracil and oxaliplatin versus 5-fluorouracil alone in locally advanced rectal cancer: First results of the German CAO/ARO/AIO-04 randomized phaseIII trial. ASCO Annual Meeting 2011, abstract 78728 2011
64. Kundel Y, Brenner R, Purim O et al. Is local excision after complete pathological response to neoadjuvant chemoradiation for rectal cancer an acceptable treatment option? Dis Colon Rectum 2010 53 1624-1631
65. Habr-Gama A, Perez R O., Wynn G et al. Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 2010 53 1692-1698
66. Hiotis S P., Weber S M., Cohen A M. et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488patients. J Am Coll Surg 2002 194 131-135 discussion 135-136
67. Sprenger T, Rothe H, Jung K et al. StageII/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification? World J Surg Oncol 2010 8 27-27
68. Sprenger T, Rothe H, Langer C et al. Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens - results from a prospective evaluation with extensive pathological work-up. J Gastrointest Surg 2010 14 96-103
69. Habr-Gama A, Perez R O., Nadalin W et al. Operative versus nonoperative treatment for stage0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004 240 711-717 discussion 717-718
70. Habr-Gama A. Assessment and management of the complete clinical response of rectal cancer to chemoradiotherapy. Colorectal Dis 2006 8 21-24
71. Habr-Gama A, Perez R O., Sabbaga J et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009 52 1927-1934
72. Yeo S G., Kim D Y., Kim T H. et al. Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 2010 252 998-1004
73. Collette L, Bosset J F., den Dulk M et al. Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. J Clin Oncol 2007 25 4379-4386 (Pubitemid 350013843)
74. Collette L et al. Correspondence. J Clin Oncol 2008 26 508-509
75. Cionini L et al. Final results of a randomized trial on adjuvant chemotherapy after preoperative chemoradiation in rectal cancer. Radiother Oncol 2010 96 Abstract 299.
76. Comment on: CapirciC, ValentiniV, CioniniL, De PaoliA, RodelC, Glynne-JonesR, CocoC, RomanoM, MantelloG, PalazziS, MattiaFO, FrisoML, GenovesiD, VidaliC, GambacortaMA, BuffoliA, LupattelliM, FavrettoMS, La TorreG. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566ypCR patients. Int J Radiat Oncol Biol Phys 2008; 72: 99-107
77. Bujko K, Glynne-Jones R, Bujko M. Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials. Ann Oncol 2010 21 1743-1750
78. Rectal cancer V.2. NCCN Clinical Practical Guidelines in Oncology 2010 http://www.nccn.org/professionals/physician-gls/PDF/rectal.pdf
79. Glimelius B, Oliveira J. Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009 20 54-56
80. Francois Y, Nemoz C J., Baulieux J et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol 1999 17 2396
81. Veenhof A A., Kropman R H., Engel A F. et al. Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery. Int J Colorectal Dis 2007 22 507-513 (Pubitemid 46488055)
82. Tulchinsky H, Shmueli E, Figer A et al. An interval>7weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 2008 15 2661-2667
83. De Campos-Lobato L F., Geisler D P., da Luz Moreira A et al. Neoadjuvant therapy for rectal cancer: The impact of longer interval between chemoradiation and surgery. J Gastrointest Surg 2011 15 444-450
84. Moore H G., Gittleman A E., Minsky B D. et al. Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum 2004 47 279-286 (Pubitemid 38280578)
85. Dolinsky C M., Mahmoud N N., Mick R et al. Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. JSurg Oncol 2007 96 207-212 (Pubitemid 350194618)
86. Lim S B., Choi H S., Jeong S Y. et al. Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg 2008 248 243-251
87. Kalady M F., de Campos-Lobato L F., Stocchi L et al. Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 2009 250 582-589
88. Garcia-Aguilar J, Smith D D., Avila K, et al., on behalf of the Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: Preliminary results of a multicenter, nonrandomized phaseII prospective trial. Ann Surg 2011 254 97-102
89. Habr-Gama A, Perez R O., Sabbaga J et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period. Dis Colon Rectum 2009 52 1927-1934
90. Fernandez-Martos C, Pericay C, Aparicio J et al. PhaseII, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus Oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3study. J Clin Oncol 2010 28 859-865
91. Ghadimi B M., Grade M, Difilippantonio M J. et al. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 2005 23 1826-1838 (Pubitemid 46217459)
92. Liersch T, Grade M, Gaedcke J et al. Preoperative chemoradiotherapy in locally advanced rectal cancer: correlation of a gene expression-based response signature with recurrence. Cancer Genet Cytogenet 2009 190 57-65
93. Ghadimi B M., Grade M. Cancer gene profiling for response prediction. Methods Mol Biol 2010 576 327-339
94. Grade M, Hummon A B., Camps J et al. A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets. Int J Cancer 2011 128 1069-1079
95. Liersch T, Gaedcke J, Grade M et al. Molekulare Marker zur Responseprädiktion beim lokal fortgeschrittenen Rektumkarzinom. Kommt die Individualisierung der Therapie? Der Onkologe 2010 16 779-788
96. Grade M, Gaedcke J, Wangsa D et al. Chromosomal copy number changes of locally advanced rectal cancers treated with preoperative chemoradiotherapy. Cancer Genet Cytogenet 2009 193 19-28
97. Grade M, Ghadimi B M., Varma S et al. A massive aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. Cancer Res 2006 66 267-282 (Pubitemid 43166033)
98. Gaedcke J, Grade M, Jung K et al. KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy. Radiother Oncol 2010 94 76-81
99. Gaedcke J Grade M, Jung K et al. Mutated KRAS results in overexpression of DUSP4, a MAP-kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas. Genes Chromosomes Cancer 2010 49 1024-1034
100. Conradi L C., Bleckmann A, Schirmer M et al. Thymidylate Synthase as a Prognostic Biomarker for Locally Advanced Rectal Cancer after multimodal Treatment. Ann Surg Oncol 2011 [Epub ahead of print]
101. Sprenger T Rödel F, Beissbarth T et al. Failure of down-regulation of Survivin following neoadjuvant radiochemotherapy in rectal cancer is associated with distant metastases and shortened survival. Clin Cancer Res 2011 17 1623-1631
102. Sobin L H., Wittekind C. TNM classification of malignant tumors. Berlin Springer 2002
103. Merkel S, Mansmann U, Papadopoulos T et al. The prognostic inhomogeneity of colorectal carcinomas StageIII: a proposal for subdivision of StageIII. Cancer 2001 92 2754-2759 (Pubitemid 33091911)
104. Merkel S, Mansmann U, Siassi M et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001 16 298-304 (Pubitemid 32927002)
105. Chan A K., Wong A, Jenken D et al. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005 61 665-677 (Pubitemid 40247960)
106. Quah H M., Chou J F., Gonen M et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 2008 113 57-64 (Pubitemid 351976386)
107. Fietkau R, Barten M, Klautke G et al. Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer. Dis Colon Rectum 2006 49 1284-1292 (Pubitemid 44401376)